Research Progress of RUNX3 in Gynecological Oncology

doi:10.12280/gjfckx.20201031

Abstract

Abstract:

Cervical cancer, endometrial cancer and ovarian cancer are the three most common malignant tumors in gynecology, which seriously threaten the life and safety of women. DNA methylation is one of the important epigenetic mechanisms, which can lead to the silencing of tumor suppressor genes and ultimately lead to tumorigenesis. RUNX3 is one of the hot topics in the research of tumor suppressor genes, which plays an important role in cell growth, proliferation, differentiation, apoptosis and signal transduction. RUNX3 promoter methylation will lead to its expression silence, which plays an important role in the occurrence and development of gynecological tumors. Methylation inhibitors can induce the re-expression of RUNX3 to achieve the purpose of tumor treatment. The occurrence, growth and metastasis of tumor are closely related to the internal and external environment of tumor cells, which will form a unique tumor microenvironment. RUNX3 can regulate it through a variety of actions. With the further study of the mechanism of RUNX3 in gynecological tumors, it will lay a foundation for it to become a diagnostic marker and targeted therapy of gynecological tumors. To summarize the research progress of RUNX3 in gynecological tumors, in order to provide new ideas for clinical work.

Key words: RUNX3, Genital neoplasms,female, DNA methylation, DNA-binding proteins, Tumor microenvironment

HE Hong-yue, TAN Wen-hua. Research Progress of RUNX3 in Gynecological Oncology[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 438-442.

References 31

[1]	Ito Y, Bae SC, Chuang LS. The RUNX family: developmental regulators in cancer[J]. Nat Rev Cancer, 2015, 15(2):81-95. doi: 10.1038/nrc3877. doi: 10.1038/nrc3877
[2]	王磊. RUNX3基因甲基化和去甲基化与肿瘤的研究进展[J]. 实用临床医学, 2018, 19(6):95-97. doi: 10.13764/j.cnki.lcsy.2018.06.038. doi: 10.13764/j.cnki.lcsy.2018.06.038
[3]	Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors[J]. Cancer Sci, 2003, 94(3):230-234. doi: 10.1111/j.1349-7006.2003.tb01425.x. doi: 10.1111/j.1349-7006.2003.tb01425.x
[4]	Lee SH, Hyeon DY, Yoon SH, et al. RUNX3 methylation drives hypoxia-induced cell proliferation and antiapoptosis in early tumorigenesis[J]. Cell Death Differ, 2021, 28(4):1251-1269. doi: 10.1038/s41418-020-00647-1. doi: 10.1038/s41418-020-00647-1
[5]	Steponaitis G, Kazlauskas A, Vaitkienė P, et al. Oncosuppressive Role of RUNX3 in Human Astrocytomas[J]. J Oncol, 2019, 2019:1232434. doi: 10.1155/2019/1232434. doi: 10.1155/2019/1232434 pmid: 31467531
[6]	Jeong D, Kim H, Ryu A, et al. Loss of RUNX3 is significantly associated with advanced tumor grade and stage in endometrial cancers[J]. Mol Med Rep, 2018, 17(6):8173-8179. doi: 10.3892/mmr.2018.8915. doi: 10.3892/mmr.2018.8915
[7]	Moon JW, Lee SK, Lee JO, et al. Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells[J]. Anticancer Res, 2014, 34(1):133-140.
[8]	Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues[J]. Blood, 2004, 104(8):2224-2234. doi: 10.1182/blood-2004-03-1109. doi: 10.1182/blood-2004-03-1109 pmid: 15231578
[9]	Chen F, Liu X, Bai J, et al. The emerging role of RUNX3 in cancer metastasis (Review)[J]. Oncol Rep, 2016, 35(3):1227-1236. doi: 10.3892/or.2015.4515. doi: 10.3892/or.2015.4515
[10]	Manandhar S, Lee YM. Emerging role of RUNX3 in the regulation of tumor microenvironment[J]. BMB Rep, 2018, 51(4):174-181. doi: 10.5483/bmbrep.2018.51.4.033. doi: 10.5483/bmbrep.2018.51.4.033 pmid: 29429451
[11]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. doi: 10.3322/caac.21262. doi: 10.3322/caac.21262
[12]	祁美霞. 宫颈癌的发病机制、诊断及治疗研究现状及进展[J]. 中国误诊学杂志, 2019, 14(10):479-480.
[13]	Li Z, Fan P, Deng M, et al. Erratum: The roles of RUNX3 in cervical cancer cells in vitro[J]. Oncol Lett, 2019, 17(3):3035. doi: 10.3892/ol.2019.9883. doi: 10.3892/ol.2019.9883
[14]	Gao QQ, Zhou B, Yu XZ, et al. Transcriptome changes induced by RUNX3 in cervical cancer cells in vitro[J]. Oncol Lett, 2020, 19(1):651-662. doi: 10.3892/ol.2019.11128. doi: 10.3892/ol.2019.11128
[15]	唐莉菲, 陈海伦, 杨慧艳. 血浆RUNx3启动子甲基化对宫颈癌早期诊断的意义[J]. 四川医学, 2016, 38(8):867-870. doi: 10.16252/j.cnki.issn1004-0501-2016.08.009. doi: 10.16252/j.cnki.issn1004-0501-2016.08.009
[16]	李朦, 张岩, 那飞, 等. RUNX3和VEGF在宫颈癌组织中的表达及相关性[J]. 现代肿瘤医学, 2018, 26(15):2430-2434. doi: 10.3969/j.issn.1672-4992.2018.15.029. doi: 10.3969/j.issn.1672-4992.2018.15.029
[17]	戴云峰. RUNX3和VEGF在宫颈癌组织中的表达分析[J]. 中国医药指南, 2020, 18(9):43-44.
[18]	陈海伦, 孙颖, 唐莉菲. 血浆RUNX3基因启动子甲基化检测对宫颈癌早期诊断的价值研究[J]. 中国实用医药, 2020, 15(5):10-12. doi: 10.14163/j.cnki.11-5547/r.2020.05.004. doi: 10.14163/j.cnki.11-5547/r.2020.05.004
[19]	谢幸, 孔北华, 段涛, 等. 妇产科学[M]. 9版. 北京: 人民卫生出版社, 2018: 307.
[20]	Makker A, Goel MM. Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update[J]. Endocr Relat Cancer, 2016, 23(2):R85-R111. doi: 10.1530/ERC-15-0218. doi: 10.1530/ERC-15-0218
[21]	Witek Ł, Janikowski T, Gabriel I, et al. Analysis of microRNA regulating cell cycle-related tumor suppressor genes in endometrial cancer patients[J]. Hum Cell, 2020 Oct 29. doi: 10.1007/s13577-020-00451-6. doi: 10.1007/s13577-020-00451-6
[22]	王劲红, 杜林, 蒋萍, 等. 子宫内膜癌组织Runx3、Twist1表达与临床病理特点及预后的关系[J]. 山东医药, 2020, 60(13):5-8. doi: 10.3969/j.issn.1002-266X.2020.13.002. doi: 10.3969/j.issn.1002-266X.2020.13.002
[23]	Cornel K, Wouters K, Van de Vijver KK, et al. Gene Promoter Methylation in Endometrial Carcinogenesis[J]. Pathol Oncol Res, 2019, 25(2):659-667. doi: 10.1007/s12253-018-0489-2. doi: 10.1007/s12253-018-0489-2
[24]	Berrino F. The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies[J]. Ann Oncol, 2003, 14(Suppl 5):v9-v13. doi: 10.1093/annonc/mdg750. doi: 10.1093/annonc/mdg750
[25]	Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes[J]. Nat Rev Cancer, 2011, 11(10):719-725. doi: 10.1038/nrc3144. doi: 10.1038/nrc3144
[26]	Häfner N, Steinbach D, Jansen L, et al. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer[J]. Int J Cancer, 2016, 138(1):217-228. doi: 10.1002/ijc.29690. doi: 10.1002/ijc.29690
[27]	Paudel D, Zhou W, Ouyang Y, et al. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer[J]. Gene, 2016, 586(1):48-55. doi: 10.1016/j.gene.2016.04.001. doi: 10.1016/j.gene.2016.04.001
[28]	Heinze K, Kritsch D, Mosig AS, et al. Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants[J]. Int J Mol Sci, 2018, 19(1):253. doi: 10.3390/ijms19010253. doi: 10.3390/ijms19010253
[29]	Barghout SH, Zepeda N, Vincent K, et al. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells[J]. Gynecol Oncol, 2015, 138(3):647-655. doi: 10.1016/j.ygyno.2015.07.009. doi: 10.1016/j.ygyno.2015.07.009 pmid: 26186909
[30]	Levin G, Zigron R, Haj-Yahya R, et al. Granulosa cell tumor of ovary: A systematic review of recent evidence[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 225:57-61. doi: 10.1016/j.ejogrb.2018.04.002. doi: 10.1016/j.ejogrb.2018.04.002
[31]	Chen H, Crosley P, Azad AK, et al. RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line[J]. Int J Mol Sci, 2019, 20(14):3471. doi: 10.3390/ijms20143471. doi: 10.3390/ijms20143471